<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00594854</url>
  </required_header>
  <id_info>
    <org_study_id>PN400-303</org_study_id>
    <nct_id>NCT00594854</nct_id>
  </id_info>
  <brief_title>Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec</brief_title>
  <official_title>6-Month, Randomized, Double-blind, Parallel-group, Controlled, Multi-center Study of Gastric Ulcer Incidence With PN400 (Esomeprazole/Naproxen) Versus Diclofenac/Misoprostol in Subjects at High Risk for Developing NSAID-Associated Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>POZEN</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>POZEN</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, double-blind, parallel-group, controlled, multi-center clinical trial of 6
      months duration is designed to assess the efficacy, tolerability and safety of PN400 versus
      diclofenac/misoprostol in subjects at high risk for developing NSAID-associated gastric
      ulcers. Approximately 100 sites will participate to enroll a total of 200 subjects (100 per
      arm).

      At least 20% of the subjects enrolled will be age 65 years and older.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the incidence of gastric ulcers following administration of PN 400 in a high
      risk population over six months. Diclofenac/misoprostol will be used as a positive control.

      Secondary:

        -  To determine the incidence of duodenal ulcers during treatment with PN 400 and
           diclofenac/misoprostol in a high risk population

        -  To evaluate the degree of upper gastrointestinal injury as measured by Lanza scores
           (1991) during treatment with PN400 and diclofenac/misoprostol in a high risk population

        -  To compare gastrointestinal symptoms in subjects treated with PN 400 versus
           diclofenac/misoprostol as measured by scores on the Gastrointestinal Symptoms Rating
           Scale (GSRS) instrument

        -  To evaluate the safety and tolerability of PN400 and diclofenac/misoprostol in a high
           risk population
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    POZEN agreed with FDA to stop study due to low and inadequate enrollment
  </why_stopped>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Gastric Ulcer Confirmed by Endoscopy</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with gastric ulcers confirmed by endoscopy following administration of PN 400 (VIMOVO) or Arthrotec in a high risk population over six months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Duodenal Ulcers Confirmed by Endoscopy</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with duodenal ulcers confirmed by endoscopy following administration of PN 400 VIMOVO)or Arthrotec in a high risk population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Upper Gastro-intestinal Injury Grade 4 as Measured by Lanza (1991) Score</measure>
    <time_frame>6 months</time_frame>
    <description>The degree of upper gastrointestinal (UGI) injury as measured by Lanza scores (1991) during treatment with PN 400 and ARTHROTEC速 in a high-risk population. The Lanza (1991) score is based on endoscopic obeservations and rating these, with no damage, petecchiae, erosions and ulcers. On the 1991 scale, a Lanza score of 0 represents normal mucosa (no damage), while a score of 4 indicates 6-10 erosions, and a score of 7 indicates an ulcer.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Gastric Ulcer</condition>
  <arm_group>
    <arm_group_label>PN400</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PN 400 (esomeprazole/naproxen) dosed twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diclofenac/Misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>diclofenac 75mg/misoprostol 200 mcg dosed twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PN400 (VIMOVO)</intervention_name>
    <description>PN400 tablet (500 mg delayed-release naproxen/20 mg immediate-release esomeprazole) given by mouth twice daily (bid).</description>
    <arm_group_label>PN400</arm_group_label>
    <other_name>Vimovo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac/Misoprostol</intervention_name>
    <description>Over-encapsulated ARTHROTEC速 75 (75 mg diclofenac sodium/200 mcg misoprostol) capsules given by mouth bid.</description>
    <arm_group_label>Diclofenac/Misoprostol</arm_group_label>
    <other_name>Arthrotec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or non-pregnant female subjects, 18 years and older with a history of
             osteoarthritis, rheumatoid arthritis, ankylosing spondylitis or other medical
             condition expected to require daily NSAID therapy for at least 6 months, with a
             documented history of an ulcer related serious upper gastrointestinal event such as
             bleeding, perforation or obstruction

          2. Female subjects are eligible for participation in the study if they are of:

               -  Non-childbearing potential (i.e., physiologically incapable of becoming
                  pregnant);

               -  Childbearing potential, have a negative pregnancy test at screening, and at least
                  one of the following applies or is agreed to by the subject:

                    -  Female sterilization or sterilization of male partner; or,

                    -  Hormonal contraception by oral route, implant, injectable, vaginal ring; or,

                    -  Any intrauterine device (IUD) with published data showing that the lowest
                       expected failure rate is less than 1% per year;

                    -  Double barrier method (2 physical barriers or 1 physical barrier plus
                       spermicide); or

                    -  Any other method with published data showing that the lowest expected
                       failure rate is less than 1% per year

          3. Each subject must be able to understand and comply with study procedures required of a
             subject and is able and willing to provide written informed consent prior to any study
             procedures being performed

        Exclusion Criteria:

          1. History of hypersensitivity to esomeprazole or to another proton-pump inhibitor

          2. History of allergic reaction or intolerance to any NSAID (including aspirin) and/or a
             history of NSAID-induced symptoms of asthma, rhinitis, and/or nasal polyps

          3. Positive test result for H. pylori at screening

          4. Participation in any study of an investigational treatment in the 4 weeks before
             screening

          5. Presence of uncontrolled acute or chronic medical illness, e.g. gastrointestinal
             disorder, hypertension, diabetes, thyroid disorder, depression and/or infection that
             would endanger a subject if they were to participate in the study

          6. Gastrointestinal disorder or surgery leading to impaired drug absorption

          7. Evidence of uncontrolled, or unstable cardio- or cerebrovascular disorder, which in
             the investigator's opinion would endanger a subject if they were to participate in the
             study

          8. Schizophrenia or bipolar disorder

          9. Use of any excluded concomitant medication (see Section 9.2)

         10. A recent history (in the past 3 months) suggestive of alcohol or drug abuse or
             dependence, including overuse/abuse of narcotics for management of pain

         11. Serious blood coagulation disorder, including use of systemic anticoagulants

         12. Screening endoscopy showing &gt;10 erosions or any gastric or duodenal ulcer at least 3
             mm in diameter with depth

         13. Screening laboratory ALT or AST value &gt; 2 times the upper limit of normal

         14. Estimated creatinine clearance &lt; 50 ml/min

         15. Other than noted specifically, any screening laboratory value that is clinically
             significant in the investigator's opinion and would endanger a subject if they were to
             participate in the study

         16. History of malignancy, treated or untreated, within the past 5 years, with the
             exception of successfully treated basal cell or squamous cell carcinoma of the skin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Everardus Orlemans, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>POZEN</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>POZEN</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2007</study_first_submitted>
  <study_first_submitted_qc>January 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2008</study_first_posted>
  <results_first_submitted>May 28, 2010</results_first_submitted>
  <results_first_submitted_qc>August 27, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 22, 2010</results_first_posted>
  <last_update_submitted>August 27, 2010</last_update_submitted>
  <last_update_submitted_qc>August 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Everardus Orlemans, PhD, VP, Clinical Research</name_title>
    <organization>POZEN Inc</organization>
  </responsible_party>
  <keyword>NSAID</keyword>
  <keyword>Gastric Ulcer</keyword>
  <keyword>High risk</keyword>
  <keyword>Arthrotec</keyword>
  <keyword>Vimovo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Stomach Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Arthrotec</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Multi-center US study, 16 sites recruited subjects between November 2007 and June 2008. On May 2, 2008 POZEN reached agreement with the FDA to terminate the study based on difficulty in recruiting subjects.</recruitment_details>
      <pre_assignment_details>Screening for eligibility and wash-out of restricted medications.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PN400 (VIMOVO)</title>
          <description>PN 400 (esomeprazole/naproxen) dosed twice daily (bid)</description>
        </group>
        <group group_id="P2">
          <title>Arthrotec</title>
          <description>diclofenac/misoprostol dosed twice daily (bid)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2">POZEN reached an agreement with the FDA to terminate the study due to low and inadequate enrollment.</participants>
                <participants group_id="P2" count="1">POZEN reached an agreement with the FDA to terminate the study due to low and inadequate enrollment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study terminated</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PN400 (VIMOVO)</title>
          <description>PN 400 (esomeprazole/naproxen) dosed twice daily (bid)</description>
        </group>
        <group group_id="B2">
          <title>Arthrotec</title>
          <description>diclofenac/misoprostol dosed twice daily (bid)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.2" spread="9.5"/>
                    <measurement group_id="B2" value="54.4" spread="17.2"/>
                    <measurement group_id="B3" value="58.4" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Duodenal Ulcers Confirmed by Endoscopy</title>
        <description>Number of participants with duodenal ulcers confirmed by endoscopy following administration of PN 400 VIMOVO)or Arthrotec in a high risk population</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PN400 (VIMOVO)</title>
            <description>PN 400 (esomeprazole/naproxen) dosed twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Arthrotec</title>
            <description>diclofenac/misoprostol dosed twice daily (bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Duodenal Ulcers Confirmed by Endoscopy</title>
          <description>Number of participants with duodenal ulcers confirmed by endoscopy following administration of PN 400 VIMOVO)or Arthrotec in a high risk population</description>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="33.6"/>
                    <measurement group_id="O2" value="1" lower_limit="0.2" upper_limit="41.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Gastric Ulcer Confirmed by Endoscopy</title>
        <description>Number of participants with gastric ulcers confirmed by endoscopy following administration of PN 400 (VIMOVO) or Arthrotec in a high risk population over six months.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PN400 (VIMOVO)</title>
            <description>PN 400 (esomeprazole/naproxen) dosed twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Arthrotec</title>
            <description>diclofenac/misoprostol dosed twice daily (bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Gastric Ulcer Confirmed by Endoscopy</title>
          <description>Number of participants with gastric ulcers confirmed by endoscopy following administration of PN 400 (VIMOVO) or Arthrotec in a high risk population over six months.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Upper Gastro-intestinal Injury Grade 4 as Measured by Lanza (1991) Score</title>
        <description>The degree of upper gastrointestinal (UGI) injury as measured by Lanza scores (1991) during treatment with PN 400 and ARTHROTEC速 in a high-risk population. The Lanza (1991) score is based on endoscopic obeservations and rating these, with no damage, petecchiae, erosions and ulcers. On the 1991 scale, a Lanza score of 0 represents normal mucosa (no damage), while a score of 4 indicates 6-10 erosions, and a score of 7 indicates an ulcer.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PN400 (VIMOVO)</title>
            <description>PN 400 (esomeprazole/naproxen) dosed twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Arthrotec</title>
            <description>diclofenac/misoprostol dosed twice daily (bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Upper Gastro-intestinal Injury Grade 4 as Measured by Lanza (1991) Score</title>
          <description>The degree of upper gastrointestinal (UGI) injury as measured by Lanza scores (1991) during treatment with PN 400 and ARTHROTEC速 in a high-risk population. The Lanza (1991) score is based on endoscopic obeservations and rating these, with no damage, petecchiae, erosions and ulcers. On the 1991 scale, a Lanza score of 0 represents normal mucosa (no damage), while a score of 4 indicates 6-10 erosions, and a score of 7 indicates an ulcer.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data collection were planned at 1, 3 and 6 months. In May 2008 POZEN reached an agreement with the FDA to terminate the study due to low and inadequate enrollment. No 6 month adverse events data were collected.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PN400 (VIMOVO)</title>
          <description>PN 400 (esomeprazole/naproxen) dosed twice daily (bid)</description>
        </group>
        <group group_id="E2">
          <title>Arthrotec</title>
          <description>diclofenac/misoprostol dosed twice daily (bid)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis Erosive</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Erosive duodenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to small number of subjects.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Clinical Research</name_or_title>
      <organization>Pozen Inc.</organization>
      <phone>919-913-1030</phone>
      <email>eorlemans@pozen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

